Lupin and MonoSol Rx tie up for pediatric products
DSIJ Intelligence / 06 Oct 2016
Lupin’s US subsidiary, Lupin Pharmaceutical Inc., and MonoSol Rx have entered into a strategic licensing agreement. The company would develop multiple pediatric products utilising MonoSol Rx’s proprietary PharmFilm drug delivery technology.
Lupin’s US subsidiary, Lupin Pharmaceutical Inc., and MonoSol Rx have entered into a strategic licensing agreement. The company would develop multiple pediatric products utilising MonoSol Rx’s proprietary PharmFilm drug delivery technology.
MonoSol Rx’s PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film. MonoSol Rx is a global leader in film based drug delivery applications with two FDA-approved products and a robust pipeline of pharmaceuticals in development.
PharmFilm technology will be used to treat patients who may have difficulty swallowing pills or tolerating medication in traditional delivery forms. This provides a minimally invasive alternative to pills, injections, and gels, with the goal of helping patients adhere to their prescribed treatment regimens in order to improve their health.
The share price of Lupin increased by 0.77 per cent on bourses in early trades; and is trading at Rs 1488.5 on an intraday basis.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.